Q-omics provides the consensus-scored MAST2 profile across patient tissues and cancer cell-line models. MAST2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MAST2 is differentially expressed in 16, with the highest sampling consensus in LIHC. Additionally, MAST2 RNA expression shows 20,029 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where MAST2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAST2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAST2 survival associations across molecular data types. MAST2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAST2 RNA expression–survival associations across cancer types. High MAST2 expression shows unfavorable associations in KIRP, MESO, ACC, LIHC, KICH and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MAST2 RNA expression.
This table summarizes MAST2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAST2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAST2 shows lower tumor expression in COAD and higher tumor expression in LIHC, LUAD, THCA, LUSC and KIRC. The LIHC box plot shows higher MAST2 RNA expression in tumor versus normal tissue (log2 FC = +1.551, t-test p < 0.001).
This table shows molecular features associated with MAST2 in patient tissues and cancer cell lines. In patient samples, MAST2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAST2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
